GlassScriptPhysician profile
Puneet K Gupta
NPI 1942402466
$14,250.46
in general payments reported to CMS, 2019-2025
27 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $3,262 · 2021: $9,770 · 2022: $353 · 2023: $193 · 2024: $242 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $12,735.38 | 2020-2021 | |
| Immedica Pharma US, INC. | $172.05 | 2023 | |
| Neuropace, INC. | $157.54 | 2019 | |
| Ucb, INC. | $154.91 | 2019-2022 | |
| Lilly USA, LLC | $148.89 | 2024-2025 | Kisunla |
| Omniscient Neurotechnology America LTD | $126.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $114.71 | 2021-2022 | |
| Pfizer INC. | $108.09 | 2023-2025 | |
| Monteris Medical Corporation | $66.65 | 2019 | |
| Abbvie INC. | $62.32 | 2022 | |
| Zimmer Biomet Holdings, INC. | $56.67 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $40.64 | 2022 | |
| Biogen, INC. | $35.90 | 2020-2021 | |
| Argenx US, INC. | $33.58 | 2025 | Vyvgart Hytrulo |
| Microtransponder, INC. | $31.99 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $24.02 | 2024 | |
| Livanova USA, INC. | $22.41 | 2022 | |
| Adamas Pharmaceuticals, INC. | $22.23 | 2020 | |
| Life Molecular Imaging LTD | $20.29 | 2024 | Neuraceq |
| Aquestive Therapeutics, INC. | $19.31 | 2021 | |
| Greenwich Biosciences, INC. | $19.05 | 2021 | |
| Allergan, INC. | $18.78 | 2020 | |
| Acadia Pharmaceuticals INC | $18.27 | 2020 | |
| Ge Healthcare | $17.47 | 2019 | |
| Xeris Pharmaceuticals, INC. | $11.83 | 2021 | |
| Genzyme Corporation | $11.48 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.